Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 17/20 | 0.48 |
| ▸ | HTR1B | P28222 | 15/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR1F | P30939 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8723889 | 0.92 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8721855 | 0.87 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1F | |
| SCHEMBL8724231 | 0.85 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FHTR6 | |
| SCHEMBL7482535 | 0.84 | HTR1D (0.53) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8721060 | 0.83 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8723990 | 0.82 | HTR1D (0.50) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8720833 | 0.81 | HTR1D (0.51) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8720670 | 0.81 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8721017 | 0.80 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL8724109 | 0.80 | HTR1D (0.50) | HTR1DHTR1BHTR1AHTR1FCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1D 3/4885HTR1B 4/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.